Orange Book product · Generic (ANDA)
PAZOPANIB HYDROCHLORIDE
PAZOPANIB HYDROCHLORIDE
Generic (ANDA)ANDA 217517TE ABRX TEVA PHARMS INC
At a glance
Oct 19, 2023
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 19, 2023
2 yr 8 mo ago
Today
Pharmaceutical detail
Active ingredient
PAZOPANIB HYDROCHLORIDE
Strength
EQ 200MG BASE
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 217517
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of PAZOPANIB HYDROCHLORIDE
- 2009VOTRIENTBrand (NDA)
NDA 022465 · NOVARTIS
- 2025PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 219922 · TORRENT
- 2024PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 219034 · EUGIA PHARMA
- 2024PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 218231 · NOVUGEN
- 2023PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 217713 · APOTEX
- 2023PAZOPANIB HYDROCHLORIDEGeneric (ANDA)
ANDA 215837 · SUN PHARM
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
